Codice QR

Asciminib as first-line therapy in chronic myeloid leukemia: a systematic review

Abstract Purpose Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the BCR::ABL1 fusion oncogene. Asciminib, a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor, represents a novel therapeutic approach distinct from conventional ATP-compe...

Descrizione completa

Salvato in:
Autori principali: Jae Joon Han, Jeong-Ok Lee, Kyoung Ha Kim, Sung-Eun Lee, Sang Kyun Sohn, Chul Won Jung, Hawk Kim, The Korean Society of Hematology Chronic Myeloid Leukemia Working Party
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Nature 2026-07-01
Serie:Blood Research
Soggetti:
Asciminib
Chronic myeloid leukemia
First-line therapy
BCR::ABL1
Tyrosine kinase inhibitor
Molecular response
Accesso online:https://doi.org/10.1007/s44313-026-00153-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi